Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases

James A. Neidhart, Susan A. Anderson, Jules E. Harris, John J. Rinehart, John Laszlo, Francisco H. Dexeus, Lawrence Einhorn, Donald L. Trump, Pasquale W. Benedetto, Richard L. Tuttle, Richard V. Smalley

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

One hundred sixty-five patients were randomized to receive either Interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of Interferon given at daily doses of 3, 5, 20, 20, and 20 × 106 U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/2 (later decreased to 5 mg/2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.

Original languageEnglish (US)
Pages (from-to)832-836
Number of pages5
JournalJournal of Clinical Oncology
Volume9
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Vinblastine
Kidney Neoplasms
Neoplasm Metastasis
Lung
Survival
Interferons
Therapeutics
Research
interferon alfa-n1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neidhart, J. A., Anderson, S. A., Harris, J. E., Rinehart, J. J., Laszlo, J., Dexeus, F. H., ... Smalley, R. V. (1991). Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases. Journal of Clinical Oncology, 9(5), 832-836.

Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases. / Neidhart, James A.; Anderson, Susan A.; Harris, Jules E.; Rinehart, John J.; Laszlo, John; Dexeus, Francisco H.; Einhorn, Lawrence; Trump, Donald L.; Benedetto, Pasquale W.; Tuttle, Richard L.; Smalley, Richard V.

In: Journal of Clinical Oncology, Vol. 9, No. 5, 1991, p. 832-836.

Research output: Contribution to journalArticle

Neidhart, JA, Anderson, SA, Harris, JE, Rinehart, JJ, Laszlo, J, Dexeus, FH, Einhorn, L, Trump, DL, Benedetto, PW, Tuttle, RL & Smalley, RV 1991, 'Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases', Journal of Clinical Oncology, vol. 9, no. 5, pp. 832-836.
Neidhart, James A. ; Anderson, Susan A. ; Harris, Jules E. ; Rinehart, John J. ; Laszlo, John ; Dexeus, Francisco H. ; Einhorn, Lawrence ; Trump, Donald L. ; Benedetto, Pasquale W. ; Tuttle, Richard L. ; Smalley, Richard V. / Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 5. pp. 832-836.
@article{36422f4aa92643ec8432de244f650e97,
title = "Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases",
abstract = "One hundred sixty-five patients were randomized to receive either Interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of Interferon given at daily doses of 3, 5, 20, 20, and 20 × 106 U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/2 (later decreased to 5 mg/2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10{\%} with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44{\%}. Responses were durable, and overall survival of this group was much better than that of the other patients.",
author = "Neidhart, {James A.} and Anderson, {Susan A.} and Harris, {Jules E.} and Rinehart, {John J.} and John Laszlo and Dexeus, {Francisco H.} and Lawrence Einhorn and Trump, {Donald L.} and Benedetto, {Pasquale W.} and Tuttle, {Richard L.} and Smalley, {Richard V.}",
year = "1991",
language = "English (US)",
volume = "9",
pages = "832--836",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Vinblastine fails to improve response of renal cancer to interferon alfa-n1 high response rate in patients with pulmonary metastases

AU - Neidhart, James A.

AU - Anderson, Susan A.

AU - Harris, Jules E.

AU - Rinehart, John J.

AU - Laszlo, John

AU - Dexeus, Francisco H.

AU - Einhorn, Lawrence

AU - Trump, Donald L.

AU - Benedetto, Pasquale W.

AU - Tuttle, Richard L.

AU - Smalley, Richard V.

PY - 1991

Y1 - 1991

N2 - One hundred sixty-five patients were randomized to receive either Interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of Interferon given at daily doses of 3, 5, 20, 20, and 20 × 106 U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/2 (later decreased to 5 mg/2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.

AB - One hundred sixty-five patients were randomized to receive either Interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of Interferon given at daily doses of 3, 5, 20, 20, and 20 × 106 U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/2 (later decreased to 5 mg/2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.

UR - http://www.scopus.com/inward/record.url?scp=0025763734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025763734&partnerID=8YFLogxK

M3 - Article

C2 - 2016626

AN - SCOPUS:0025763734

VL - 9

SP - 832

EP - 836

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -